

CERTIFICATE OF MAILING	
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date appearing below.	
By <i>KS Rhodes</i>	Date <i>10-14-03</i>
ELI LILLY AND COMPANY	

PATENT APPLICATION
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants	:	Charles Jack Fisher, et al.)	
Serial No.	:	09/842,337)	
Filing Date	:	April 25, 2001)	Group Art Unit:
)	1651
For	:	Method of Treating Viral Hemorrhagic Fever)	Examiner:
)	J. Weber
Docket No.	:	X-12449A)	

RECEIVED

INFORMATION DISCLOSURE STATEMENT

OCT 20 2003

TECH CENTER 1600/2990

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

As a means of complying with the duty of disclosure, Applicants submit an "Information Disclosure Citation In An Application" on a Form PTO-1449 (modified) and provides a copy of each of the listed documents for consideration by the Examiner.

Since this Statement is being filed in accordance with 37 C.F.R. 1.97(b), Applicants submit that no additional fee is required.

Applicants request consideration of this information.

Respectfully submitted,

Thomas E. LaGrandeur
Thomas E. LaGrandeur
Attorney for Applicants
Registration No. 51,026
Phone: 317-651-1527

Eli Lilly and Company
Patent Division/TEL
P.O. Box 6288
Indianapolis, Indiana 46206-6288

October 14, 2003



FORM PTO 1449 (modified) INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Atty. Docket No. X-12449A	Serial No 09/842,337
	Applicants Charles Jack Fisher, et al	
	Filing Date April 25, 2001	Group 1651

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. 1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Pages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	AA				
	AB				
	AC				
	AD				
	AE				
	AF				
	AG				
	AH				
	AI				
	AJ				
	AK				
	AL				
	AM				
	AN				
	AO				
	AP				
	AQ				
	AR				

RECEIVED

OCT 20 2003

TECH CENTER 1600/2000



Sheet 2 of 3

FORM PTO 1449 (modified) INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Atty. Docket No. X-12449A	Serial No 09/842,337
	Applicants Charles Jack Fisher, et al	
	Filing Date April 25, 2001	Group 1651


FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. 1	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ - Kind Code ⁵ (if known)				
	BA					
	BB					
	BC					
	BD					
	BE					
	BF					
	BG					
	BH					
	BI					
	BJ					
	BK					
	BL					
	BM					
	BN					
	BO					
	BP					
	BQ					
	BR					

RECEIVED

OCT 20 2003

TECH CENTER 1600/2500



FORM PTO 1449 (modified)	Atty. Docket No.	Serial No
	X-12449A	09/842,337
	Applicants	
	Charles Jack Fisher, et al	
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Filing Date	Group
	April 25, 2001	1651

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s) publisher, city and/or country where published.	T ⁶
	CD	Takazoe, K. et al., "Association of Plasma Levels of Activated Protein C with Recanalization of the Infarct-Related Coronary Artery After Thrombolytic Therapy in Acute Myocardial Infarction" <u>Thrombosis Research</u> Vol. 95, 37-47 (1999)	
	CE	Granger, C. , et al., "Rebound Increase in Thrombin Generation and Activity After Cessation of Intravenous Heparin In patients With Acute Coronary Syndromes" <u>Circulation</u> , Vol. 91, No 7 1929-1935 (1995)	
	CF	Mesters, R. et al., "Factor VIIa and Antithrombin III Activity During Severe Sepsis and Septic Shock in Neutropenic Patients" <u>Blood</u> , Vol 88, No. 3 881-886 (1996)	
	CG	Mesters, R., et al., "Prognostic value of protein C concentrations in neutropenic patients at high risk of severe septic complications" <u>Crit Care Med</u> , Vol 28 No. 7, 2209-2216 (2000)	
	CH	Kleijn, E., et al., "Activation of protein following infusion of protein C concetrate in children with sever meningococcal sepsis and purpura fulminans: A randomized, double-blinded, placebo-controlled, dose finding study" <u>Crit Care Med</u> , Vol 31, No. 6, 1839-1847 (2003)	
	CI	Gerson, W. et al. "Severe Acquired Protein C Deficiency in Purpura Fulminans Associated with Disseminated Intravascular Coagulation: Treatment with Protein C Concentrate" <u>Pediatrics</u> , Vol. 91, No. 2, 418-422 (1993)	
	CJ	Rivard, G. et al., "Treatment of purpura fulminans in meningococcemia with protein C concentrate" <u>J. of Pediatrics</u> , Vol 126, No 4, 646-652 (1995)	
	CK	Rintala, R., et al., "Protein C in the treatment of coagulopathy in meningococcal disease" <u>Crit. Care Med.</u> , Vol. 26, No. 5, 965-968 (1998)	
	CL	EMA "Committee For Proprietary Medicinal Products European Public Assessment Report (EPAR) CEPROTIN Abstract – CPMP/1383/01 (2001)	
	CM		
	CN		
Examiner Signature	Date Considered		

RECEIVED

OCT 20 2003

TECH CENTER 1600/2000

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hours Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.